International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.
Comparing the current state of M&A to what it looked like pre-pandemic, Cheryl says, "It's bounced back, but in a more thoughtful and less-frenzied way. Licensing deals, as a prelude to and stepped approach to M&A, have always been popular in this industry, but we are seeing this more, as it reduces the risk for big pharma."
Source
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
